Shooting Cancer

4 08, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – July 2022

adlitterio663392022-08-04T09:42:52+02:00

Read More

18 07, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – June 2022

adlitterio663392022-07-18T11:28:45+02:00

Read More

27 06, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – May 2022

adlitterio663392022-06-27T12:11:23+02:00

Read More

20 05, 2022

Monthly focus on regulatory status of new targeted therapies in oncology – April 2022

Diatech Pharmacogenetics2022-05-20T11:08:27+02:00

Read More

12 04, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- March 2022

Diatech Pharmacogenetics2022-04-12T17:29:57+02:00

Read More

12 04, 2022

ALK rearrangements: a biomarker at the forefront of NSCLC treatment

Diatech Pharmacogenetics2022-04-12T12:17:10+02:00

Read More

17 03, 2022

Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology February 2022

Diatech Pharmacogenetics2022-03-24T12:38:58+01:00

Read More

23 02, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- January 2022

Diatech Pharmacogenetics2022-04-12T17:30:48+02:00

Read More

26 01, 2022

Monthly focus on regulatory status of new targeted therapies in oncology- December 2021

Diatech Pharmacogenetics2022-01-27T17:29:30+01:00

Read More

21 12, 2021

Shooting Cancer – Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November 2021

Diatech Pharmacogenetics2021-12-21T17:17:52+01:00

Read More